<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04463901</url>
  </required_header>
  <id_info>
    <org_study_id>20150527</org_study_id>
    <nct_id>NCT04463901</nct_id>
  </id_info>
  <brief_title>Conjunctival Autograft or Limbal Conjunctival Autograft for Recurrent Pterygium Using Mitomycin C</brief_title>
  <official_title>Intraoperative Mitomycin C Combined With Conjunctival Autograft or Limbal Conjunctival Autograft for Recurrent Pterygium: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized clinical trial is to compare the efficacy and safety of
      intraoperative mitomycin C(MMC) combined with limbal conjunctival autograft(LCAG) or
      conjunctival autograft(CAG) for recurrent pterygium surgery. The investigators will also
      evaluate particular risk factors related to pterygium recurrence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intraoperative mitomycin C after pterygium excision is widely used to prevent recurrce of
      recurrent pterygium. Conjunctival autograft with or without limbal tissue used to cover the
      bare sclera will efficiently reduce postoperative longstanding epithelial defect.

      Patients with recurrent pterygium will be randomly assigned to undertake pterygium excision
      followed by intraoperative mitomycin C with conjunctival autograft or limbal conjunctival
      autograft .The patients will be followed at least 12 months. Corneal recurrence is considered
      as a fibrovascular ingrowth beyond the limbus with conjunctival drag in the area of previous
      pterygium excision.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of pterygium</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing time of corneal epithelium</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing time of conjunctival epithelium</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Recurrent Pterygium</condition>
  <arm_group>
    <arm_group_label>Group CAG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After pterygium excision, intraoperative mitomycin c (0.02%) for 5 minutes will be applied topically onto the exposed surgical area and then conjunctival autograft without limbal tissue will be used to cover the bare sclera.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group LCAG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After pterygium excision, intraoperative mitomycin c (0.02%) for 5 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft will be used to cover the bare sclera.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pterygium excision</intervention_name>
    <description>Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.</description>
    <arm_group_label>Group CAG</arm_group_label>
    <arm_group_label>Group LCAG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intraoperative mitomycin C</intervention_name>
    <description>Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.</description>
    <arm_group_label>Group CAG</arm_group_label>
    <arm_group_label>Group LCAG</arm_group_label>
    <other_name>MMC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conjunctival autograft</intervention_name>
    <description>A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.</description>
    <arm_group_label>Group CAG</arm_group_label>
    <other_name>CAG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Limbal conjunctival autograft</intervention_name>
    <description>A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.</description>
    <arm_group_label>Group LCAG</arm_group_label>
    <other_name>LCAG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent pterygium

          -  Willingness to participate in research project and to attend research time

          -  At least 6 months after last pterygium surgery

        Exclusion Criteria:

          -  Pregnant,breast-feeding women or poor general health

          -  Patients with significant ocular or lid pathology, such as Sjogren's Syndrome
             ,infection, exposure keratitis,glaucoma and trauma

          -  Patients with allergy to mitomycin C,tobramycin or local anesthetics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhou Shiyou, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhou Shiyou, M.D., Ph.D.</last_name>
    <phone>86-02087331540</phone>
    <email>zhoushiy@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhou Tao, M.D.</last_name>
    <phone>86-18126813938</phone>
    <email>taochou_tony@foxmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiyou Zhou, M.D., Ph.D.</last_name>
      <phone>86-02087331550</phone>
      <email>zhoushiy@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Tao Zhou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 4, 2020</study_first_submitted>
  <study_first_submitted_qc>July 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>July 4, 2020</last_update_submitted>
  <last_update_submitted_qc>July 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Shiyou Zhou</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>recurrent pterygium</keyword>
  <keyword>pterygium</keyword>
  <keyword>limbal conjunctival autograft</keyword>
  <keyword>conjunctival autograft</keyword>
  <keyword>mitomycin c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

